Sterilizing Grade Filtration Patents: Who Leads, Trends 2026
Sterilizing Grade Filtration Patents: Concentration at the Top, a Cooling Trend
73.3% of all 288 records sit with just five assignees, and the leader alone accounts for 118 records — this is a field with an entrenched core, not an open one. Filings peaked at 35 in 2017 and have declined since; the -74% move from 23 filings in 2021 to 6 in 2024 marks the last year the trend can be read as complete, since 2025 and 2026 are still filling in under normal publication lag.
- 1EMD MILLIPORE CORP118
- 2TEVA PHARMA IND LTD53
- 3NXSTAGE MEDICAL INC19
- 4ENTEGRIS INC11
- 5MERCK MILLIPORE LTD10
See the full sterilizing grade filtration analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about sterilizing grade filtration patents
Who holds the most patents in sterilizing grade filtration?
One assignee holds 118 of the 288 records in this dataset, far ahead of the fifth-ranked filer at 10 records. The top five assignees combined account for 73.3% of all 288 records in scope, and the top ten hold 86.1%. This level of concentration means most foundational filter validation and membrane integrity claims are already staked by a small number of long-established filers.
Is patent filing in sterilizing filtration still growing?
No — filings peaked in 2017 at 35 and have fallen since, with the last complete comparison showing a drop from 23 filings in 2021 to 6 in 2024, a 74% decline. Several of the largest historical filers show zero filings in the most recent tracked year. Figures for 2025 and 2026 are still incomplete because publication typically lags filing by about 18 months, so a full rebound cannot be ruled out, but the multi-year trend through 2024 is clearly downward.
What technology areas do sterilizing filtration patents cover?
Separation processes under IPC class B01D appear in 52.8% of the 288 records, making membrane and filter housing design the dominant technical theme. But medicinal preparation claims (A61K, 26.7%) and sterilising method claims (A61L, 17.4%) are also common, showing that many patents combine a filtration element with a drug formulation or a sterilizing process rather than claiming filter hardware alone. Material testing methods (G01N, 14.2%) reflect the significant share of the field devoted to validation methodology.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Sterilizing Grade Filtration covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.